AMG 531
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Conditions
Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Trial Timeline
Nov 1, 2006 → Sep 1, 2011
NCT ID
NCT00440037About AMG 531
AMG 531 is a phase 2/3 stage product being developed by Kyowa Kirin for Immune (Idiopathic) Thrombocytopenic Purpura (ITP). The current trial status is completed. This product is registered under clinical trial identifier NCT00440037. Target conditions include Immune (Idiopathic) Thrombocytopenic Purpura (ITP).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00440037 | Phase 2/3 | Completed |
Competing Products
20 competing products in Immune (Idiopathic) Thrombocytopenic Purpura (ITP)